OUR MISSION STATEMENT

The mission of the University at Buffalo School of Pharmacy and Pharmaceutical Sciences is to educate students in pharmacy practice and the pharmaceutical sciences, to create and disseminate knowledge in pharmacy practice and the pharmaceutical sciences, to provide patient care, and to provide services to the community-at-large based upon this knowledge. This mission is to be achieved consistent with the highest ethical standards and with respect for diversity and cultural sensitivity.

The mission recognizes pharmaceutical care as a mode of pharmacy practice within the health-care team in which the patient is empowered “to achieve the desired outcomes of drug and related therapy.”

The mission also recognizes that research in the broad area of the clinical sciences, pharmaceutical sciences, and education is necessary to create and maintain a body of knowledge needed for professional education, health-care delivery, and the advancement of science. In this context, our goal is to enhance the local, national, and international leadership of the School of Pharmacy and Pharmaceutical Sciences and continue it as one of the strong components of the University at Buffalo and the State University of New York system. This will involve a focus on those areas of unique strength within the school and those areas that form unique, interdisciplinary bridges within the university.

Care and discovery, core objectives of the School of Pharmacy and Pharmaceutical Sciences, are being advanced through expanded, enhanced programs and innovative research. The result advances the school’s vaulted position, in keeping with the University at Buffalo’s leadership path toward the top ranks of public research universities.

This annual report traces the strength, leadership, and innovation that have characterized the past year for the SoPPS—a dramatic progression poised to continue.
Message from the Dean

Enhancement and innovation were encompassing themes in 2006–07.

Expansion of our PharmD Experiential Programs to provide students in all years of our program with off-site clinical educational experiences has been a major focus. This focus has brought with it the need for additional faculty as well as preceptors. We have begun active recruiting efforts in both these areas.

The enhancement of our programs also precipitated the need to continually strengthen and infuse school leadership. Edward Bednarczyk, PharmD, associate professor, pharmacy practice, was appointed chair of pharmacy practice and the former chair, Gene Morse, PharmD, expanded the role of associate dean for clinical and translational research. Both these positions are key to the future success of the school in allowing our pharmacy-driven academic and research areas strong insightful leadership. Another new leadership appointment within the school was the appointment of Jennifer Hess, PhD, as our assistant dean for admissions. This strategic hire will enhance the balance and focus for all admissions activities here at the school.

Innovation was a major theme evidenced by our researchers. Joseph Balthasar, associate professor, pharmaceutical sciences, has begun to lay the foundation for the Center for Protein Therapeutics upon receiving strong funding from many partners during the 2006–07 academic year. This funding will allow the center to begin hiring graduate and postdoctoral students to enhance the education of future proteomic researchers, as well as have an immediate impact on current research and analysis.

UB 2020 and associated growth to all divisions on campus brings with it the opportunity for expansion, enhancement, and innovation through all aspects of our university life. Increased enrollment driving increases in faculty, staff, and facilities will create changes in our curriculum, research activities, scholarship, and outreach. The possibilities are limitless. We welcome your partnership and support as we begin this new phase at UB and the SoPPS.

Thank you,

Wayne K. Anderson
Professor and Dean
In the world of twenty-first-century health care, many take up the challenge of optimizing the discovery and delivery of new pharmacotherapy. At the UB School of Pharmacy and Pharmaceutical Sciences, Joseph Balthasar and Patty Havard are among the leaders of that cadre.

Bench to bedside, bedside to bench, their research on protein therapeutics and antiretroviral pharmacology among HIV-positive pregnant women, respectively, is advancing pharmacokinetics (PK) and pharmacodynamics (PD) knowledge. Together, they are cultivating hope among patient populations where previously there was little.
He explains that Gerhard Levy, a pioneer of modern PK/PD research, was a member of the SoPPS Department of Pharmaceutical Sciences faculty and that SoPPS Distinguished Professor William Jusko is an international leader in the discovery and advancement of PK/PD knowledge. “It could be argued that most of the important pharmacokinetic and dynamic research since the ’60s had its start at Buffalo, from this department, largely because of Gerhard Levy, Bill Jusko, and others in the department.”

Center for Protein Therapeutics

Balthasar’s research also has drawn both industry and scientific attention in the field. His visionary work with monoclonal antibodies led to the development of a new UB Center for Protein Therapeutics; the institution was his idea during meetings of SoPPS faculty to identify strengths in their school as part of the UB 2020 strategic planning process.

The Center for Protein Therapeutics is scheduled to formally open in June 2008 at UB’s New York State Center of Excellence in Bioinformatics and Life Sciences in downtown Buffalo. The facility is envisioned to position UB as the first university worldwide with a multidisciplinary program focusing on the application of pharmaceutical sciences to the development of protein drugs.

UB’s protein therapeutics effort, which was spearheaded by a $1 million grant from Novartis, is funded by a consortium of pharmaceutical industry leaders that were impressed by UB’s protein therapeutics research and the capacity of the SoPPS for grooming PK/PD professionals to meet future industry demand. Over the next ten years, protein therapeutics is expected to comprise as much as 50 percent of the new drugs approved by the FDA.

Antibodies in action

“In my laboratory, we’re interested in the treatment of cancers and autoimmune diseases,” says Balthasar, a Buffalo native and UB SoPPS alumnus who earned his BS degree in pharmacy in 1991 and PhD in pharmaceutics in 1996. “My group is very interested in understanding the pharmacokinetics and pharmacodynamics of monoclonal antibody drugs.”

Balthasar’s research also has drawn both industry and scientific attention in the field. His visionary work with monoclonal antibodies led to the development of a new UB Center for Protein Therapeutics; the institution was his idea during meetings of SoPPS faculty to identify strengths in their school as part of the UB 2020 strategic planning process.

The Center for Protein Therapeutics is scheduled to formally open in June 2008 at UB’s New York State Center of Excellence in Bioinformatics and Life Sciences in downtown Buffalo. The facility is envisioned to position UB as the first university worldwide with a multidisciplinary program focusing on the application of pharmaceutical sciences to the development of protein drugs.

UB’s protein therapeutics effort, which was spearheaded by a $1 million grant from Novartis, is funded by a consortium of pharmaceutical industry leaders that were impressed by UB’s protein therapeutics research and the capacity of the SoPPS for grooming PK/PD professionals to meet future industry demand. Over the next ten years, protein therapeutics is expected to comprise as much as 50 percent of the new drugs approved by the FDA.

Center for Protein Therapeutics

Balthasar’s research also has drawn both industry and scientific attention in the field. His visionary work with monoclonal antibodies led to the development of a new UB Center for Protein Therapeutics; the institution was his idea during meetings of SoPPS faculty to identify strengths in their school as part of the UB 2020 strategic planning process.

The Center for Protein Therapeutics is scheduled to formally open in June 2008 at UB’s New York State Center of Excellence in Bioinformatics and Life Sciences in downtown Buffalo. The facility is envisioned to position UB as the first university worldwide with a multidisciplinary program focusing on the application of pharmaceutical sciences to the development of protein drugs.

UB’s protein therapeutics effort, which was spearheaded by a $1 million grant from Novartis, is funded by a consortium of pharmaceutical industry leaders that were impressed by UB’s protein therapeutics research and the capacity of the SoPPS for grooming PK/PD professionals to meet future industry demand. Over the next ten years, protein therapeutics is expected to comprise as much as 50 percent of the new drugs approved by the FDA.

Antibodies in action

“In my laboratory, we’re interested in the treatment of cancers and autoimmune diseases,” says Balthasar, a Buffalo native and UB SoPPS alumnus who earned his BS degree in pharmacy in 1991 and PhD in pharmaceutics in 1996. “My group is very interested in understanding the pharmacokinetics and pharmacodynamics of monoclonal antibody drugs.”

Balthasar’s research also has drawn both industry and scientific attention in the field. His visionary work with monoclonal antibodies led to the development of a new UB Center for Protein Therapeutics; the institution was his idea during meetings of SoPPS faculty to identify strengths in their school as part of the UB 2020 strategic planning process.

The Center for Protein Therapeutics is scheduled to formally open in June 2008 at UB’s New York State Center of Excellence in Bioinformatics and Life Sciences in downtown Buffalo. The facility is envisioned to position UB as the first university worldwide with a multidisciplinary program focusing on the application of pharmaceutical sciences to the development of protein drugs.

UB’s protein therapeutics effort, which was spearheaded by a $1 million grant from Novartis, is funded by a consortium of pharmaceutical industry leaders that were impressed by UB’s protein therapeutics research and the capacity of the SoPPS for grooming PK/PD professionals to meet future industry demand. Over the next ten years, protein therapeutics is expected to comprise as much as 50 percent of the new drugs approved by the FDA.

Antibodies in action

“In my laboratory, we’re interested in the treatment of cancers and autoimmune diseases,” says Balthasar, a Buffalo native and UB SoPPS alumnus who earned his BS degree in pharmacy in 1991 and PhD in pharmaceutics in 1996. “My group is very interested in understanding the pharmacokinetics and pharmacodynamics of monoclonal antibody drugs.”

Balthasar’s research also has drawn both industry and scientific attention in the field. His visionary work with monoclonal antibodies led to the development of a new UB Center for Protein Therapeutics; the institution was his idea during meetings of SoPPS faculty to identify strengths in their school as part of the UB 2020 strategic planning process.

The Center for Protein Therapeutics is scheduled to formally open in June 2008 at UB’s New York State Center of Excellence in Bioinformatics and Life Sciences in downtown Buffalo. The facility is envisioned to position UB as the first university worldwide with a multidisciplinary program focusing on the application of pharmaceutical sciences to the development of protein drugs.

UB’s protein therapeutics effort, which was spearheaded by a $1 million grant from Novartis, is funded by a consortium of pharmaceutical industry leaders that were impressed by UB’s protein therapeutics research and the capacity of the SoPPS for grooming PK/PD professionals to meet future industry demand. Over the next ten years, protein therapeutics is expected to comprise as much as 50 percent of the new drugs approved by the FDA.

Antibodies in action

“In my laboratory, we’re interested in the treatment of cancers and autoimmune diseases,” says Balthasar, a Buffalo native and UB SoPPS alumnus who earned his BS degree in pharmacy in 1991 and PhD in pharmaceutics in 1996. “My group is very interested in understanding the pharmacokinetics and pharmacodynamics of monoclonal antibody drugs.”

Balthasar’s research also has drawn both industry and scientific attention in the field. His visionary work with monoclonal antibodies led to the development of a new UB Center for Protein Therapeutics; the institution was his idea during meetings of SoPPS faculty to identify strengths in their school as part of the UB 2020 strategic planning process.

The Center for Protein Therapeutics is scheduled to formally open in June 2008 at UB’s New York State Center of Excellence in Bioinformatics and Life Sciences in downtown Buffalo. The facility is envisioned to position UB as the first university worldwide with a multidisciplinary program focusing on the application of pharmaceutical sciences to the development of protein drugs.

UB’s protein therapeutics effort, which was spearheaded by a $1 million grant from Novartis, is funded by a consortium of pharmaceutical industry leaders that were impressed by UB’s protein therapeutics research and the capacity of the SoPPS for grooming PK/PD professionals to meet future industry demand. Over the next ten years, protein therapeutics is expected to comprise as much as 50 percent of the new drugs approved by the FDA.

Antibodies in action

“In my laboratory, we’re interested in the treatment of cancers and autoimmune diseases,” says Balthasar, a Buffalo native and UB SoPPS alumnus who earned his BS degree in pharmacy in 1991 and PhD in pharmaceutics in 1996. “My group is very interested in understanding the pharmacokinetics and pharmacodynamics of monoclonal antibody drugs.”

Balthasar’s research also has drawn both industry and scientific attention in the field. His visionary work with monoclonal antibodies led to the development of a new UB Center for Protein Therapeutics; the institution was his idea during meetings of SoPPS faculty to identify strengths in their school as part of the UB 2020 strategic planning process.

The Center for Protein Therapeutics is scheduled to formally open in June 2008 at UB’s New York State Center of Excellence in Bioinformatics and Life Sciences in downtown Buffalo. The facility is envisioned to position UB as the first university worldwide with a multidisciplinary program focusing on the application of pharmaceutical sciences to the development of protein drugs.

UB’s protein therapeutics effort, which was spearheaded by a $1 million grant from Novartis, is funded by a consortium of pharmaceutical industry leaders that were impressed by UB’s protein therapeutics research and the capacity of the SoPPS for grooming PK/PD professionals to meet future industry demand. Over the next ten years, protein therapeutics is expected to comprise as much as 50 percent of the new drugs approved by the FDA.

Antibodies in action

“In my laboratory, we’re interested in the treatment of cancers and autoimmune diseases,” says Balthasar, a Buffalo native and UB SoPPS alumnus who earned his BS degree in pharmacy in 1991 and PhD in pharmaceutics in 1996. “My group is very interested in understanding the pharmacokinetics and pharmacodynamics of monoclonal antibody drugs.”

Balthasar’s research also has drawn both industry and scientific attention in the field. His visionary work with monoclonal antibodies led to the development of a new UB Center for Protein Therapeutics; the institution was his idea during meetings of SoPPS faculty to identify strengths in their school as part of the UB 2020 strategic planning process.

The Center for Protein Therapeutics is scheduled to formally open in June 2008 at UB’s New York State Center of Excellence in Bioinformatics and Life Sciences in downtown Buffalo. The facility is envisioned to position UB as the first university worldwide with a multidisciplinary program focusing on the application of pharmaceutical sciences to the development of protein drugs.
“WE’RE NOT REINVENTING THE WHEEL,” Balthasar says of his own research. “We’re just using the wheels to drive a new car. We’ve adapted these methodologies, and then applied them to our purposes. And the ideas that we get all come from pharmacokinetics and pharmacodynamics.”

In the lab, Balthasar and his research team use “fairly basic instrumentation” to engineer antibodies that are monospecific—proteins that will clone only to select targets. As he talks of spinning together cancer cells with genetically altered B-lymphocyte cells to create monoclonal proteins with selective affinity, he draws a diagram to better illustrate the far-reaching possibilities of protein therapeutics.

“In the lab, Balthasar and his research team use ‘fairly basic instrumentation’ to engineer antibodies that are monospecific—proteins that will clone only to select targets. As he talks of spinning together cancer cells with genetically altered B-lymphocyte cells to create monoclonal proteins with selective affinity, he draws a diagram to better illustrate the far-reaching possibilities of protein therapeutics.

“Pharmacokinetic and dynamic analyses allow us to understand systems in a very quantitative and mathematical way. If you understand things well enough to be able to develop models to describe them, you can begin to unravel complex mechanisms of drug effect, and you develop a clear picture of how a therapy is working,” he explains.

“What we’ve done is investigate a therapy, IVIG, that is useful in the treatment of many autoimmune diseases. We found a mechanism that was previously unknown that was responsible for its action. And then we developed more specific, more selective ways to be able to use that mechanism to get rid of the pathogenic antibodies.”

Improving ovarian cancer treatment

Balthasar also is using that mechanism to find ways to improve survival rates for ovarian cancer. Ovarian cancer is among the most difficult to treat because it spreads in microscopic tumor colonies from the ovaries to sites throughout the peritoneal cavity.

“Systemic toxicity limits the amount of chemotherapeutic drug that can be given to dose levels that aren’t high enough to cure the disease,” he explains. “We’ve been developing antibodies against the chemotherapeutic drugs. We give the chemotherapeutic drug directly into the peritoneum where the cancer resides, so it’s active where it’s needed. When the drug is absorbed into the bloodstream, the antibody, which is a protein therapeutic, binds to it and prevents it from causing toxicity.”

Reducing HIV threat to offspring

At bedside, Patty Havard is pursuing new pharmacotherapeutic knowledge as it relates to the use of antiretroviral drugs in HIV-positive women to reduce transmission of the virus from mother to child.

“The current guidelines recommend a combination therapy of three antiretroviral drugs to reduce perinatal transmission of the HIV virus from the mother to the infant,” she explains. “My clinical research is to better characterize the pharmacokinetics of these drugs during pregnancy, and some of the factors influencing their distribution across the placenta.”

Havard earned her doctoral degree in pharmacy from the University of the Pacific and was a fellow at Columbus Children’s Hospital in Ohio. Her clinical interest in therapeutics for HIV and AIDS-associated opportunistic infections was sparked while she was a member of the Rutgers University faculty. Her current clinical work with HIV-positive pregnant women began at Ohio State University, where she was part of the faculty in the Department of Obstetrics and Gynecology before coming to UB in 2006. At the SoPPS, she is research division head of pharmacotherapy research programs and associate professor of pharmacy practice.

During her tenure at Ohio State University (OSU), Havard collaborated with the Division of Infectious Diseases and the Department of Obstetrics and Gynecology (of which she is still a faculty member) in the College of Medicine, and with Columbus Children’s Hospital, to implement an HIV high-risk pregnancy program. The multidisciplinary clinic was the first of its kind in the state. “HIV
pharmacotherapeutics really is a specialty that requires a close working relationship with infectious disease specialists, nurses, microbiologists, and other health-care providers,” Havard said in a 2007 interview.

Dramatic decline in HIV births

Over the last six years, Havard’s powerful clinical work has translated to the birth of more than 100 HIV-free infants to HIV-positive mothers and helped to reduce HIV births from 25 percent to less than 2 percent.

“As a pharmacist, I help to identify barriers as to why the moms are not taking their medications. Adherence to antiretroviral therapy is critical for optimal outcomes. Non-adherence can lead to drug resistance and increase the risk of HIV transmissions from the mother to the baby. Drug-drug interactions, drug-food interactions, laboratory tests, and maternal-adverse events are assessed at each clinic visit to ensure successful treatment with antiretroviral therapy,” Havard says.

The participants in her clinical research are referred through women’s clinics at the Erie County Medical Center (ECMC), and delivered at Women and Children’s Hospital of Buffalo: Havard has a clinical practice at both locations. The women are predominantly African-American or from African nations, uninsured or publicly insured, and unaware that they are HIV-positive until the pregnancy is confirmed. Although usually in the early stages of HIV infection, they are treated with a regimen of protease inhibitors to improve the chance of their baby being born HIV-free.

Monitoring perinatal drug distribution

Potent antiretroviral drugs such as atanzanavir, zidovudine, and lamivudine, among others, are used routinely to reduce HIV morbidity and mortality in nonpregnant adult women. Despite limited safety data, these drugs also are recommended for HIV-infected pregnant women to reduce perinatal transmission of the virus. To give hope to new generations, Havard is developing a comprehensive outcomes database to monitor drug safety and optimize pharmacotherapy.

“We really don’t know much about the factors influencing drug distribution in the fetal compartment,” Havard says, adding that many antiretroviral drugs work at the intracellular level. “We now know that there is a transporter protein that pumps out HIV protease inhibitors from intracellular cytoplasm. This effect could be a potential mechanism for drug failure. The protein is known as the p-glycoprotein, and the question is, Is p-glycoprotein even expressed in a fetal cell?”

To answer this key question, Havard and her collaborators are studying p-glycoprotein gene expression and HIV-protease inhibitor intracellular levels in blood samples taken from the mother and the umbilical cord at delivery.

Visionary therapeutic outcomes

Because antiretroviral therapy has transformed HIV infection into a chronic disease, the next stage of Havard’s research will examine potential drug-drug interaction between protease inhibitors and conjugated estrogens (hormone replacement therapy) among HIV-positive menopausal women.

Looking forward, she hopes to establish at UB a regional HIV-in-Women Research Network between ECMC, OSU, and the University of Rochester Medical Center, which is a member of the National Institutes of Health–funded AIDS Clinical Trials Group. “I came to UB because of the expertise in pharmacokinetics, pharmacodynamics, and pharmacogenetics,” Havard says. “I hope my clinical and research efforts, at least in small part, will improve the use of HIV medications and outcomes in HIV-infected women.”

Joe Balthasar hopes his bench work with monoclonal antibodies will continue to build on the knowledge provided by his mentors in the pharmaceutical sciences department of UB, in his hometown. When asked what started him in pursuit of better protein biotech therapy, he remembers a pharmaceutics class he took with instructor Robert Straubinger, an international research scholar in bioanalysis and proteomics who is now his academic colleague.

“We’re not reinventing the wheel,” Balthasar says of his own research. “We’re just using the wheels to drive a new car. We’ve adapted these methodologies, and then applied them to our purposes. And the ideas that we get all come from pharmacokinetics and pharmacodynamics.”

–Jessica Thorpe, Outside the Box Communications
Admissions

A central mission of the Office of Admissions is to advance the diversity and academic quality of the student body. This mission is supported by our continued review and enhancement of admissions policies and our ability to attract a robust applicant pool.

The most talented and selective undergraduate freshman class in the university’s history arrived in 2007 with the School of Pharmacy and Pharmaceutical Sciences contributing significantly to this trend with 400 students indicating pre-pharmacy as their intended major, representing over 12 percent of the incoming UB freshman class. In addition, UB’s Early Assurance Program offers outstanding pre-pharmacy undergraduates the opportunity to enter our PharmD professional program after completing two years of prerequisite coursework with a minimum GPA of 3.5. In 2007, the median GPA for early assurance students accepted to the SoPPS was 3.76.

Admissions Table Information

The UB SoPPS educates students in pharmacy and the pharmaceutical sciences, providing them with the critical thinking skills to allow them to achieve the desired outcomes of drug-related therapy and disease management through research and clinical intervention.

<table>
<thead>
<tr>
<th>Year of admission (expected year of graduation)</th>
<th>Number of completed applications</th>
<th>Number admitted</th>
<th>Average GPA</th>
<th>Average PCAT score</th>
<th>Percent (numbers) holding a baccalaureate or higher degree</th>
</tr>
</thead>
<tbody>
<tr>
<td>2002 (2006)</td>
<td>244</td>
<td>115</td>
<td>3.35</td>
<td>281*</td>
<td>36% (41)</td>
</tr>
<tr>
<td>2003 (2007)</td>
<td>384</td>
<td>117</td>
<td>3.24</td>
<td>376*</td>
<td>49% (57)</td>
</tr>
<tr>
<td>2005 (2009)</td>
<td>1,051</td>
<td>120</td>
<td>3.55</td>
<td>395</td>
<td>34% (41)</td>
</tr>
<tr>
<td>2006 (2010)</td>
<td>1,375</td>
<td>124</td>
<td>3.54</td>
<td>395</td>
<td>28% (35)</td>
</tr>
<tr>
<td>2007 (2011)</td>
<td>1,196</td>
<td>122</td>
<td>3.50</td>
<td>398</td>
<td>51% (62)</td>
</tr>
</tbody>
</table>

*SoPPS began to accept other scores (e.g., MCAT) and waive PCAT requirements for UB’s early assurance students. The GPA and PCAT scores reflect the entering class, not the entire school.
Continuing Education

Office of Postgraduate Professional Continuing Education

FISCAL YEAR 2006–07

<table>
<thead>
<tr>
<th>Program Type</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>UB Programs</td>
<td>15</td>
</tr>
<tr>
<td>UB Certificate Programs</td>
<td>1</td>
</tr>
<tr>
<td>Home Study Programs</td>
<td>1</td>
</tr>
<tr>
<td>Cosponsored</td>
<td>16</td>
</tr>
<tr>
<td>Teleconferences (five-topic series)</td>
<td>5</td>
</tr>
<tr>
<td>(offered at fifty-eight sites throughout the nation)</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>38</strong></td>
</tr>
</tbody>
</table>

The Office of Postgraduate Professional Continuing Education accredited and conducted thirty-eight pharmaceutical continuing education programs over the past twelve months. Programming includes both live and home study offerings. Five series of teleconferences were offered at fifty-eight sites throughout the nation. The postgraduate office cosponsors educational activity by accrediting pharmacy programs for nonaccredited providers, including interprofessional CE.

Certificate programs are designed to expand and enhance predetermined practice competencies through the systematic acquisition of specified knowledge, skills, attitudes, and performance behaviors. The postgraduate professional education office is currently running a certificate program focused on HIV; future plans include certificate programs in medication therapy management.

“Giving back to the school allows me to share with others what my education and professional training has provided for me.”

Dean Trzewieczynski, BS ’98
UB Continuing Education Programs and Symposia

<table>
<thead>
<tr>
<th>Date</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>8/14/06</td>
<td>Experiential Preceptor CE</td>
</tr>
<tr>
<td>10/27/06</td>
<td>Patient-focused Ambulatory Pharmaceutical Care</td>
</tr>
<tr>
<td>10/29/06</td>
<td>HIV Pharmacotherapy 2006</td>
</tr>
<tr>
<td>11/7/06</td>
<td>Patient-focused Ambulatory Pharmaceutical Care</td>
</tr>
<tr>
<td>11/9/06</td>
<td>Patient-focused Ambulatory Pharmaceutical Care</td>
</tr>
<tr>
<td>3/11/07</td>
<td>Pharmacy Law Update, Rochester</td>
</tr>
<tr>
<td>3/13/07</td>
<td>Pharmacy Law Update, Syracuse</td>
</tr>
<tr>
<td>3/15/07</td>
<td>Pharmacy Law Update, Jamestown</td>
</tr>
<tr>
<td>3/18/07</td>
<td>Pharmacy Law Update, Buffalo</td>
</tr>
<tr>
<td>5/9/07</td>
<td>Patient-focused Ambulatory Pharmaceutical Care, Rochester</td>
</tr>
<tr>
<td>5/23/07</td>
<td>Pharmacy Law Review Series Part I</td>
</tr>
<tr>
<td>5/24/07</td>
<td>Pharmacy Law Review Series Part II</td>
</tr>
<tr>
<td>6/11/07</td>
<td>To inject or inhale: That Is the Diabetes Question</td>
</tr>
<tr>
<td>6/13/07</td>
<td>Introducing Medication Management into Your Clinical Practice</td>
</tr>
</tbody>
</table>

Office of Postgraduate Education Receives Reaccreditation

The UB School of Pharmacy and Pharmaceutical Sciences Office of Continuing Pharmacy Education, under the auspice of the Office of Postgraduate Professional Continuing Education, underwent reaccreditation by the Accreditation Council for Pharmacy Education (ACPE). In January 2007, the continuing pharmacy education office received continuation as an ACPE-accredited provider for both continuing pharmacy education programming and certificate programming for a full six-year term.

Residency and Fellowship Training Programs

The Department of Pharmacy Practice residency and fellowship programs experienced growth in all programs of both general pharmacy practice and specialty areas.

The residents participated in monthly journal clubs and teaching-certificate program classes as a group, and attended department-run seminars.

Pharmaceutical Sciences Postdoctoral Fellows

Vamsi Addanki  
Mechanisms of Nitrate Tolerance
Sebastien Bihorel  
Pharmacokinetics and Pharmacodynamics in Diabetes
Jurgen Bulitta  
Pharmacokinetics and Pharmacodynamics of Antibiotics
Ying Hong  
Population PK/PD Modeling and Simulation of Therapeutic Drugs
Cornelia Landersdorfer  
Pharmacokinetics and Pharmacodynamics of Antidiabetic Drugs
Xia Lin  
Characterization of Androgen-regulated Myosin Heavy Chain Expression
Qiang Lu  
Antibody PK/PD and New Treatments for Autoimmune Diseases
Anshu Verma  
Systems Modeling of Bone Homeostasis and IFN-beta PKPD
Jun Yang  
PKPD Modeling of Anticancer Drugs
Jianping Zhang  
Pharmacogenetics of Human Reductases
Weiyan Zhang  
Construction and Expression of Chimeric Antibody
Pharmacy Practice Residents/Fellows

Victoria Aladejana, PharmD
Resident
Nuclear Medicine

Amed Amer, MD, PhD
Fellow
Drug Development/Novartis

Rebecca Bitter, PharmD
Resident
Psychiatry

Yseult Brun, PharmD
Fellow
Drug Development/Novartis

Holly Coe, PharmD
Resident
Primary Care/Buffalo Medical Group

Katherine Doyle, PharmD
Resident
Hospice/Homecare

Cara Felton, PharmD
Resident
Pharmacoinformatics

Noel Forrett, PharmD
Resident
Family Medicine

Yoriko Harigaya, PharmD
Fellow
Drug Development/GSK

Sarah McCabe, PharmD
Fellow
Drug Development/Novartis

Scott Monte, PharmD
Resident
Ambulatory Care/Lifetime Health Medical Group

Neha Sheth, PharmD
Resident
PGY2-HIV/ID

Patcharaporn Sudchada, PharmD
Fellow
Nephrology/Renal Transplantation
Pharmacotherapy

Craig Whitman, PharmD
Resident
Critical Care Medicine

Jenny Yang, PharmD
Fellow
Drug Development/Novartis

Student Supporters

The following supporters have provided generous funding for educational training of pharmacy postgraduate residents and fellows, as well as trainees in all levels of pharmaceutical sciences programming.

Pharmaceutical Sciences

PhD Students

Pfizer Global Research and Development Corporation
Melanie Tait
Surajkumar Bhansali
Abraham Anson

Amgen, Inc.
Justin Earp

Kapoor Foundation
Kavitha Bhasi

Merck & Company, Inc.
Mirelle Vanessa Gonzales
Sofia Gameiro

Sankyo Pharma, Inc.
Urvi Telang

Schering-Plough Corporation
Pei-suen Tsou

Eli Lilly & Company
Chao Xu

Postdoctoral Fellows

Pfizer Global Research and Development Corporation
Jun Yang
Ying Hong
Cornelia Landersdorfer

Johnson & Johnson Inc.
Jurgen Bulitta

“The generosity of our alumni has had a profound impact on the quality of training offered to students at the school. It is extremely gratifying to see alumni finding success in their professional careers and taking the opportunity to give back to the institution that has given them so much.”

Joseph J. Raybon, PhD ’07

Pharmacy Postgraduate Residents and Fellows

Lifetime Health Medical Group
Scott Monte

Buffalo Medical Group
Holly Coe

Novartis Pharmaceuticals Corporation
Jenny Yang
Sarah McCabe
Amed Amer
Yseult Brun

GlaxoSmithKline
Yoriko Harigaya

Metcare Rx Pharmaceutical Service Group, LLC
Cara Felton
Commencement Awards

Lilly Achievement Award
Lynn Monteleone

Phi Lambda Sigma of Achievement, Chapter Member of the Year Award
Regina Ventura

GlaxoSmithKline Patient Care Award
Kerrie Peterson

Michael E. Crawford Award
Daniel Wachowicz

Eino Nelson Award
Jodi Grillo

UB Pharmacy Alumni Association Award
Tyler Smith-Strutz

David E. Guttman Award
Chia-Ching Wu

Renee A. Dederich Award
Jeffrey Scull

Francis P. Taylor Award
Jodi Grillo

APHA-ASP Mortar & Pestle Professionalism Award (McNeil)
Kwaku Marfo

Robert H. Ritz Award
Kari Mergenhagen

National Community Pharmacists Association Outstanding Student Member Award
Charles Greenberg

Roger Mantsavinos Award
Lauren Maroni

Lori Esch Memorial Award
Regina Will

Merck Award
Kari Mergenhagen
Lynn Monteleone
Lauren Maroni

ASP National Patient Counseling Award
Patrick Comerford

Roche Pharmacy Communications Award
Ronald Rambally

Robert M. Cooper Memorial Award
Lynn Monteleone

Mylan Pharmaceutical Excellence in Pharmacy Award
Patrick Comerford

Facts and Comparisons Award of Excellence in Clinical Communication
Nathaniel Page

Roy M. Barr Award
Kari Mergenhagen

Western New York Society of Health-system Pharmacists Award
Andrea Hanson
Ekaterina Kossykh-Burrows

Samuel J. Bauda Award
Jared Reles

Pharmacists’ Society of the State of New York
Charis Gatas

Natural Medicines Comprehensive Database Recognition Award
Heather Pula

Mckesson Leadership Award
Kerrie Peterson

NYS Chapter of the American College of Clinical Pharmacy Research Award
William Loeffler

TEVA Pharmaceuticals USA Outstanding Student Award
Rachel Weber

Margaret C. Swisher Memorial Award
Jodi Grillo

A. B. Lemon Memorial Award
Diana Rutkowski

ASP Certificate of Recognition
Amanda Boeckel

Applied Pharmacotherapy Professional Experience Program Award
Kari Mergenhagen

Ambulatory Care Professional Experience Program Award
Megan Todd

Pharmacists’ Association of Western New York Student Leadership Award
Devon Benson

Perrigo Award of Excellence in Non-Prescription Medication Studies
Matthew Woltz

Kelli Jordan Memorial Award
Nathaniel Page

Excellence in Pharmacogenomics Award
Kari Mergenhagen

Excellence in Teaching Award
William Prescott, clinical assistant professor
2007 Who’s Who Among Students in American Universities and Colleges

Amanda Boeckel  
Patrick Comerford  
Charles Greenberg  
Richard Lin  
William Loeffler  
Kwaku Marfo  
Julia Markov  
Kari Mergenhagen  
Lynn Monteleone  
Priyanka Narula  
Nathaniel Page  
Kerrie Peterson  
Christina Pettapiece  
Jared Reles  
Diana Rutkowski  
Tyler Smith-Strutz  
Rabia Stevenson  
Patnawon Thung  
Julie Tracey  
Nathaniel Turck  
Regina Ventura  
Rachel Weber  
Stephen Webster  
Regina Will

Student Achievements

2007 Celebration of Academic Excellence Student Research Poster Presenters

Christine Lee  
Hoi Kei Lon  
Thu Dung (Ariane) Nguyen  
Nathan Page  
Jenna Voelinger  
Stephen Webster  
Chia-Ching Wu

Excellence in Pharmaceutical Sciences 2006

Darowan Akajabor  
James Bartlett  
Caitlin Bower  
James Catanese  
Kaitlin Ganley  
Lisa Garrity  
Nicholas Jennings  
Jessica Jones  
Andrea Keck  
Matthew Kosloski  
Deborah Liana  
Laurie Loedeman

Man Ly  
Ka Leong Mak  
Devon Marks  
Stephen Matics  
Stephanie McCutcheon  
Joseph Steblein  
Andrew Wohlrab  
Chia-Ching Wu  
Jade Yang  
Lillianna Yohonn

Nathan Page – 2007 Rho-Chi Schering Plough- AFPE Scholarship  
Patrick Comerford – J. Scott Fleming Award Finalist  
Amanda Boeckel – United States Public Health Service Excellence in Public Health Pharmacy Practice Award  
Qi Wang – Research Presentation at AAPS 2006 Annual Meeting  
Erin Knight – UB SoPPS APHA Counseling Competition Nominee  
Kari Mergenhagen – UB American Association of University Women, Olga Lindberg $10,000 Scholarship Winner  
Tricia Wilkins – 2007 AMCP/Pfizer Managed Care Internship
2006–07 SoPPS
Degree Recipients

Bachelor of Science in Pharmaceutical Sciences

February 2007
Jonathan Lamping
Kingsley Ohikuare

June 2007
Michael Amato
Thomas Barchet
Amos Chery
Matthew Kosloski
Quyen Nguyen
Oladipupo Omole
Chia Ching Wu

Bachelor of Science/Master of Science in Pharmaceutical Sciences

June 2007
Jeffrey Brado
Wing Ki Lam

Master of Science in Pharmaceutical Sciences

February 2007
Olanrewaju Okusanya

June 2007
Xiaomin Chen

Doctor of Pharmacy

September 2006
Kyungun Oh
Anita Robek
Maria Sakach

February 2007
Anna D’Alessandro
Shafiq Lavji
Kimberly Popplewell

June 2007
Robert Adams
Jennifer Alberico
Robert Angelo
Danielle Bader
Rebecca Becker
Devon Benson
Amanda Boeckel
Elizabeth Briggs
Lucas Bryk
Kimberly Cashion
Lisa Chaloux
Patrick Comerford
Kathleen Connolly
Eric Cudzil
Sarah Darlak
Nicole Dean
Kevin DiGiacomo
Colleen Domn
Milad Elchibani
Michelle Foster
Charis Gatas
Charles Greenberg
Jodi Grillo
Brian Gucwa
Jason Guffey
Cheryl Haag
Christine Han
Kelly Hannigan
Andrea Hanson
Shanti Hinson
Bradley Hoffman
Alison Hynes
Mavis Jasmine
Melissa Jeancy
Michael Johnson
Susan Kang
Stacy Kesy
Kathleen Kittleison
Jaycee Koo
Janine Kosmoski
Ekaterina Kossykh-Burrows
Evon Kowal
Natalie Kremer
Christine Lee
Kam Hin Lee
Wen Qiao Li
Richard Lin
William Loeffler
Michael MacEvoy
Michelle Mangaser
Kwaku Marfo
Julia Markov
Lauren Maroni
Robert Maynard
Tracy Mendan
Kari Mengenahan
Amy Jo Michnik
Lynn Monteleone
Laura Murray
Priyanka Narula
Brieanne Nichols
Navind Oodit
Todd Ordan
Richard Orlowski
Nathaniel Page
Bonnie Pellegrino
Kerrie Peterson
Lindsey Peterson
Christine Pettapiece
Jonathan Philips
Kathryn Picone
Mark Prior
Heather Pula
Rohan Raikar
Ronald Rambally
Jared Reles
Rebecca Rogers
Wendy Rose
Diana Rutkowski
Jeffrey Scull
Katie Shannon
Tyler Smith-Strutz
Kristin Spencer
Michael Spino
Rabia Stevenson
Patnawon Thung
Megan Todd
Yuet Lam Tong
Julie Tracey
Nathaniel Turk
Regina Ventura
Nicole Wahl
Rachel Weber
Stephen Webster
Nicole West
Regina Will
Matthew Woltz
Amy Wong
Ethan Wong
Theodore Yantsides

Doctor of Philosophy in Pharmaceutical Sciences

February 2007
Anasuya Hazra-Raybon
Joseph Raybon
Qi Wang
Zhenling Yao

June 2007
Kavitha Bhasi
Youngjin Moon
Wan-Jung Tsai
Pei-Suen Tsou
Sukyung Woo
Research and Training

Create cutting-edge research that enhances the body of knowledge needed for professional education, health-care delivery, and advancement of sciences that will improve the health and wellness of the global community.

Department of Pharmacy Practice: 2006–07 Annual Report

The 2006-07 year was marked by change within the Department of Pharmacy Practice. Edward Bednarczyk was named as chair in April, succeeding Gene Morse, who will remain as associate dean of translational research for the school.

Experiential Programs

The experiential program is in the process of significant revision, beginning with a revision of the assignments required of students during their P4 experiential rotations. This year has also seen the creation of the new position of director of experiential programs. Peter M. Brody Jr. has been named to fill this position. The director is charged with implementing the new introductory pharmacy practice experiential rotations for students, beginning in their P1 year. This is expected to be fully implemented in the spring 2008 semester.

Office of Postgraduate Professional Continuing Education

Our residency and fellowship programs continue to grow and mature. Over the past year we have had six fellows and nine residents in training. Seven of our current residencies have been accredited by the American Society of Health-System Pharmacists (ASHP).

A total of thirty-eight continuing education programs, representing sixty-seven contact hours, were administered through the office in the past year. An advisory board was added to gain input from practitioners regarding both the content and the format of future continuing education programs.

Research and Publication

The Department of Pharmacy Practice continues to exceed national averages for publication in the professional literature. In 2006, forty abstracts and thirty peer-reviewed journal articles were published or presented by department faculty.

The growth and scope of our programs have created a need for expansion and enhancement within our department. The department is meeting this challenge as we begin new searches for faculty in these key areas: cardiology, critical care, infectious diseases, oncology, and women’s health. The department is committed to hiring the best and brightest emerging and established faculty, allowing us to maintain excellence in both research and practice in the coming years.

Plans for significant expansion of the university have been announced by President John B. Simpson. This includes a transition back to UB’s South Campus for the school and department. As we prepare for these changes, we look forward to continued growth and the attendant challenges.

Department of Pharmaceutical Sciences: 2006–07 Annual Report

The department has an established, international reputation of excellence in teaching and research and is well positioned to expand its prowess in pharmacokinetics, pharmacodynamics, and protein therapeutics. Moreover, the department is a leading academic institute for cutting-edge research and teaching in pharmacogenomics.

The department’s strengths lie in biological applications of pharmaceutical sciences to traditional small molecules as well as biotechnology products, particularly areas of systems
pharmacology (pharmacokinetics, pharmacodynamics, pharmacogenomics), drug delivery, and development of new therapeutic approaches utilizing mechanistic studies with tools of genomics, proteomics, computation, and bioinformatics.

The implementation of the UB-Pfizer Strategic Alliance and establishment of a Center of Excellence in Pharmacokinetics and Pharmacodynamics allowed the hiring of two new assistant professors. Wojciech Krzyzanski, formerly a postdoc and research faculty member in the department, arrived in August 2006. His research emphasizes mathematical modeling of drugs that affect the hematopoietic system. Wenqing Gao, formerly a postdoc at Ohio State University, arrived in January 2007. She studies pharmacological effects of androgens and mechanisms of action of nuclear receptors.

The department boasts outstanding faculty members over a range of academic levels with highly productive, largely NIH-funded research programs and some corporate support. The school and department rank second in the U.S. in NIH research funding per PhD faculty member, according to the latest report on pharmacy faculty from the American Association of Colleges of Pharmacy (AACP). The departmental faculty brought in or shared over $2.5 million in individual and multidisciplinary grants. Donations of $200,000 for graduate student training were provided by Merck, Eli Lilly, Daiichi Sankyo, Schering-Plough, Amgen, and the Kapoor Foundation, and there was funding for six students and four postdocs by the UB-Pfizer Strategic Alliance. Joseph Balthasar received a $1 million grant from Novartis to enhance research in protein therapeutics, an area planned for future growth in the department.

An active research seminar program had over fifty presentations by local and visiting scientists. Gordon Amidon, professor of pharmaceutics at the University of Michigan, was selected for the 2006 Gerhard Levy Distinguished Lectureship in Pharmaceutical Sciences. (His presentation banquet was disrupted by Buffalo’s “October Surprise” snowstorm.) Other notable speakers during the academic year were Diane Mould of Predictions Research, Irving Wainer of the National Institute of Aging, Tristan Maurer of Pfizer Inc., and Robert Bies of the University of Pittsburgh. Juinn Lin from Merck & Co. was selected by the graduate students for the Annual Pharmaceutics Alumnus Lecture. David D’Argenio from the University of Southern California gave a two-day minicourse in the use of the Adapt program, and Robert Bauer from Xoma presented tutorials on the use of the S-Adapt software.

Faculty were active in dissemination of the department’s scientific accomplishments and knowledge. This included 102 research articles and book chapters published and 149 seminars, lectures, and research presentations delivered at various scientific meetings and university and industrial venues. Five faculty members serve as editors of journals and many participate on numerous journal editorial boards and NIH study sections.

The department offers courses in pharmacokinetic-pharmacodynamic modeling, trial simulations, and population pharmacokinetic modeling for visiting scientists from the pharmaceutical industry, academia, and the FDA each year in May. Similarly, the department offers an annual summer workshop in molecular genetic methodologies for pharmaceutical sciences. Some of these courses are also provided on site at various pharmaceutical companies and other universities. Don Mager served as a visiting professor at the University of Paris, presenting pharmacokinetics lectures over a three-week period.

Faculty recipients of special awards included William J. Jusko, chair, who was named UB Distinguished Professor, and Marilyn Morris, who received the SUNY Chancellor’s Award for Excellence in Scholarship and Creative Activities and has become associate dean for graduate and postdoctoral education at UB.

The department is poised for further growth of its research and training programs with additional faculty and graduate students and expanded capabilities in the area of protein therapeutics. In addition to our use of the Cooke-Hochstetter building, we have begun some research operations at UB’s New York State Center of Excellence in Bioinformatics and Life Sciences located in the university’s burgeoning downtown campus.
Special Honors for Faculty Members

Wayne Anderson, professor and dean, recipient, 2007 TIAA-CREF Lifetime Achievement Award.

Edward Bednarczyk, clinical associate professor, appointed chair, pharmacy practice.

Linda Catanzaro, clinical assistant professor, pharmacy practice, recipient, New York State American College of Clinical Pharmacy, 2007 Educator of the Year Award.

William Jusko, chair, pharmaceutical sciences, named UB Distinguished Professor.

Marilyn Morris, professor, pharmaceutical sciences, recipient of the SUNY Chancellor’s Award for Excellence in Scholarship and Creative Activities.

Gene Morse, professor, pharmacy practice, appointed associate dean, clinical and translational research, and also appointed International AIDS Society-USA Core Faculty member.

William Prescott, clinical assistant professor, recipient, UB SoPPS Teacher of the Year Award.

Robert Straubinger, professor, pharmaceutical sciences, elected fellow to the American Association of Pharmaceutical Scientists.

Brian Tsuji, clinical assistant professor, pharmacy practice, recipient, New York State American College of Clinical Pharmacy, 2007 Researcher of the Year Award.

Robert Wahler, clinical assistant professor, pharmacy practice, recipient, New York State American College of Clinical Pharmacy, 2007 Clinical Practitioner of the Year Award.
Faculty Grants Awarded: 2006–07

**Pharmaceutical Sciences**

Joseph Balthasar  
University of Michigan  
*Triggered Local Release of Active Thrombolytic Agents*

University of Michigan  
*PTD-Mediated Protein or Drug Delivery for Cancer Therapy*

National Institute of Allergy and Infectious Diseases  
*FCRN Inhibitors for Antibody-Mediated Immune Conditions*

Protherics Inc.  
*Benefits of Leucovorin Plus Voraxaze Versus Leucovorin Alone*

Novartis Pharma AG  
*FCRN as a Determinant of IGG Bioavailability*

Novartis Pharma AG  
*Laboratory for Protein Therapeutics*

National Cancer Institute  
*Pharmacokinetic Strategies to Optimize IP Chemotherapy*

Sathy Balu-Iyer  
National Heart, Lung, and Blood Institute  
*Development and Pharmacology of Novel Lipidic RAHF*

Javier Blanco  
National Institute of General Medical Sciences  
*Pharmacogenetics of Human Carbonyl Reductases*

City of Hope National Medical Center  
*Key Adverse Event After Childhood Cancer*

Ho-Leung Fung  
National Heart, Lung, and Blood Institute  
*Organic Nitrate Metabolism, Tolerance and Action*

Wenqing Gao  
American Association of Colleges of Pharmacy  
*Characterization of the Role of FHL-2 in Androgen Receptor (AR) Regulated Gene Expression in Cardiac Myocytes*

William Jusko  
National Institute of General Medical Sciences  
*Mathematical Models in Pharmacodynamics*

Health Research Inc.  
*Sirolimus in Acute Myeloid Leukemia: Pharmacokinetic and Pharmacodynamic Studies*

Pfizer Inc.  
*Center of Excellence in Pharmacokinetics and Pharmacodynamics*

National Institute of General Medical Sciences  
*Corticosteroid Pharmacokinetics and Pharmacodynamics*

Wojciech Krzyzanski  
Amgen Inc.  
*Amgen Postdoctoral Fellowship in PK/PD Hematology*

Donald Mager  
Amgen Inc.  
*Bone Homeostasis and IFN-Beta PK/PD*

National Institute on Aging  
*IPA Agreement for Donald Mager*

Marilyn Morris  
National Cancer Institute  
*Dietary Isothiocyanates in Cancer Prevention: Effects on Estrogen*

Murali Ramanathan  
National Multiple Sclerosis Society  
*Brain-Derived Neurotrophic Factor in Multiple Sclerosis*

Robert Straubinger  
National Cancer Institute  
*Drug Carrier Modulation of Blood/Tumor/Brain Permeability*

National Center for Research Resources  
*High Sensitivity Liquid Chromatography/Tandem Mass Spectrometry System*

PhRMA Foundation  
*Fellowship for Brian Trummer: Concentration and Exposure Dependent Mechanisms of Taxane Antitumor Action and the Tumor Resistance Response*

**Pharmacy Practice**

Edward Bednarczyk  
Pfizer Global Research and Development  
*An Open Label Phase 1 Study to Assess Central D2/D3 Receptor Occupancy Using Positron Emission Tomography (PET) Following Multiple Oral Dose Administration of PF-00217830 in the Healthy Adult*

Gene Morse  
Campbell Foundation  
*Novel Assays for Antiretroviral Intre/Extracellular Measurement*

University of Rochester  
*Adult Therapeutic Clinical Trials Program for AIDS*
GlaxoSmithKline
GlaxoSmithKline Fellowship in Support of Yoriko Harigaya
Virginia Commonwealth University
Opioids and HIV Medications: Interactions in Drug Abusers
Social and Scientific Systems Inc.
ACTG: Pharmacology Laboratory

Patrick Smith
Hoffmann-La Roche Inc.
A Multiple-Center, Open Label, Multi-Dose, Three Period, Single Sequence Crossover Study to Investigate the Potential Pharmacodynamic and Potential Pharmacokinetic Interaction Between Glyburide and R04389620 in Type 2 Diabetic (T2D) Patients Not Adequately Controlled with Glyburide as a Standard Prescribed Therapy

Novartis Pharmaceuticals Corporation
In Vitro Pharmacokinetic/Pharmacodynamics of LBH589 in Chronic Myelogenous Leukemia

Kathleen Tornatore
Novartis Pharmaceuticals Corporation
The Relationship of Drug Exposure and Immunodynamic Responses During Myfortic, Therapy in Stable African-American and Caucasians’ Renal Transplant Recipients

Brian Tsuji
Gustavus & Louise Pfeiffer Research Foundation
Novel Approaches to Combat Antibiotic-Resistant Superbug Infections

**New Technology Disclosures/Patent Applications**

<table>
<thead>
<tr>
<th>Title</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-FcRn Antibodies for Treatment of Auto/Allo Immune Conditions</td>
<td>Joseph Balthasar, Pharmaceutical Sciences</td>
</tr>
<tr>
<td>Compositions and Methods of Preparation of Lipid Nano Particulates Containing Antigens as Cancer Vaccine</td>
<td>Sathy Balu-Iyer, Pharmaceutical Sciences</td>
</tr>
<tr>
<td>Compositions and Methods of Preparation of Liposomal Microparticulate IL-12 for Immunotherapy</td>
<td>Sathy Balu-Iyer, Pharmaceutical Sciences</td>
</tr>
<tr>
<td>Method for Treating Blood Coagulation Disorders</td>
<td>Sathy Balu-Iyer, Pharmaceutical Sciences</td>
</tr>
<tr>
<td>Compositions of Less-Immunogenic and Long Circulating Protein-Lipid Complexes</td>
<td>Sathy Balu-Iyer, Pharmaceutical Sciences</td>
</tr>
<tr>
<td>Bridging Centrality: A Concept and Formula to Identify Bridging Nodes in Scale-Free Networks</td>
<td>Murali Ramanathan, Pharmaceutical Sciences</td>
</tr>
<tr>
<td>Method and Composition of Less Immunogenic Long Acting Factor VII</td>
<td>Sathy Balu-Iyer, Pharmaceutical Sciences</td>
</tr>
<tr>
<td>Method and Composition of Less Immunogenic, Long Circulating EPO</td>
<td>Sathy Balu-Iyer, Pharmaceutical Sciences</td>
</tr>
<tr>
<td>Method for Assessing Interaction in Biological Networks and Hypergraphics</td>
<td>Murali Ramanathan, Pharmaceutical Sciences</td>
</tr>
</tbody>
</table>
### Research and Training Awards
#### Fiscal Year 2006–07

#### Pharmaceutical Sciences

<table>
<thead>
<tr>
<th>Name</th>
<th>Sponsor</th>
<th>Program Type</th>
<th>Current Period</th>
<th>Project Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>J. Balthasar</td>
<td>National Institute of Allergy and Infectious Diseases</td>
<td>Continuation Research</td>
<td>$327,007</td>
<td>$1,353,537</td>
</tr>
<tr>
<td>J. Balthasar</td>
<td>University of Michigan</td>
<td>Continuation Research</td>
<td>$50,000</td>
<td>$100,000</td>
</tr>
<tr>
<td>J. Balthasar</td>
<td>University of Michigan</td>
<td>Continuation Research</td>
<td>$50,000</td>
<td>$100,000</td>
</tr>
<tr>
<td>J. Balthasar</td>
<td>National Cancer Institute</td>
<td>New Research</td>
<td>$277,164</td>
<td>$1,066,905</td>
</tr>
<tr>
<td>J. Balthasar</td>
<td>Novartis Pharma AG</td>
<td>New Research</td>
<td>$100,000</td>
<td>$100,000</td>
</tr>
<tr>
<td>J. Balthasar</td>
<td>Novartis Pharma AG</td>
<td>New Research</td>
<td>$900,000</td>
<td>$900,000</td>
</tr>
<tr>
<td>J. Balthasar</td>
<td>Protherics Inc.</td>
<td>New Research</td>
<td>$8,871</td>
<td>$8,871</td>
</tr>
<tr>
<td>S. Balu-Iyer</td>
<td>National Heart, Lung, and Blood Institute</td>
<td>Continuation Research</td>
<td>$271,422</td>
<td>$1,085,688</td>
</tr>
<tr>
<td>J. Blanco</td>
<td>National Institute of General Medical Sciences</td>
<td>Continuation Research</td>
<td>$270,516</td>
<td>$1,374,843</td>
</tr>
<tr>
<td>J. Blanco</td>
<td>City of Hope National Medical Center</td>
<td>New Research</td>
<td>$5,000</td>
<td>$5,000</td>
</tr>
<tr>
<td>J. Canty (Qu)</td>
<td>National Heart, Lung, and Blood Institute</td>
<td>Continuation Research</td>
<td>$9,268</td>
<td>$48,041</td>
</tr>
<tr>
<td>H. Fung</td>
<td>National Heart, Lung, and Blood Institute</td>
<td>Continuation Research</td>
<td>$384,759</td>
<td>$1,935,286</td>
</tr>
<tr>
<td>W. Gao</td>
<td>American Association of Colleges of Pharmacy</td>
<td>New Research</td>
<td>$10,000</td>
<td>$10,000</td>
</tr>
<tr>
<td>W. Jusko</td>
<td>National Institute of General Medical Sciences</td>
<td>Continuation Research</td>
<td>$343,819</td>
<td>$1,814,443</td>
</tr>
<tr>
<td>W. Jusko</td>
<td>Health Research Inc.</td>
<td>New Research</td>
<td>$44,879</td>
<td>$44,879</td>
</tr>
<tr>
<td>W. Jusko</td>
<td>National Institute of General Medical Sciences</td>
<td>Renewal Research</td>
<td>$253,399</td>
<td>$1,021,164</td>
</tr>
<tr>
<td>W. Jusko</td>
<td>Pfizer Inc.</td>
<td>Continuation Research</td>
<td>$1,500,000</td>
<td>$4,500,000</td>
</tr>
<tr>
<td>W. Krzyzanski</td>
<td>Amgen Inc.</td>
<td>New Training</td>
<td>$50,000</td>
<td>$50,000</td>
</tr>
<tr>
<td>D. Mager</td>
<td>National Institute on Aging</td>
<td>Continuation Research</td>
<td>$21,829</td>
<td>$62,334</td>
</tr>
<tr>
<td>D. Mager</td>
<td>Amgen Inc.</td>
<td>New Training</td>
<td>$50,000</td>
<td>$50,000</td>
</tr>
<tr>
<td>M. Morris</td>
<td>National Cancer Institute</td>
<td>New Research</td>
<td>$62,606</td>
<td>$125,213</td>
</tr>
<tr>
<td>M. Ramanathan</td>
<td>National Multiple Sclerosis Society</td>
<td>Continuation Research</td>
<td>$109,948</td>
<td>$329,845</td>
</tr>
<tr>
<td>R. Straubinger</td>
<td>National Cancer Institute</td>
<td>Supplemental Research</td>
<td>$290,879</td>
<td>$1,855,009</td>
</tr>
<tr>
<td>R. Straubinger</td>
<td>National Center for Research Resources</td>
<td>New Research</td>
<td>$500,000</td>
<td>$500,000</td>
</tr>
<tr>
<td>R. Straubinger</td>
<td>PhRMA Foundation</td>
<td>New Training</td>
<td>$18,000</td>
<td>$18,000</td>
</tr>
<tr>
<td>A. Zhang (Co-PI Ramanathan)</td>
<td>National Science Foundation</td>
<td>Continuation Research</td>
<td>$131,539</td>
<td>$569,806</td>
</tr>
</tbody>
</table>

#### Pharmaceutical Sciences Totals

|                           | $6,040,905 | $19,028,864 |
### Pharmacy Practice

<table>
<thead>
<tr>
<th>Name</th>
<th>Sponsor</th>
<th>Program Type</th>
<th>Current Period</th>
<th>Project Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>E. Bednarczyk</td>
<td>Pfizer Global Research and Development</td>
<td>New Clinical Trial</td>
<td>$504,297</td>
<td>$504,297</td>
</tr>
<tr>
<td>G. Morse</td>
<td>Virginia Commonwealth University</td>
<td>Continuation Research</td>
<td>$102,400</td>
<td>$102,400</td>
</tr>
<tr>
<td>G. Morse</td>
<td>University of Rochester</td>
<td>Continuation Research</td>
<td>$77,683</td>
<td>$77,683</td>
</tr>
<tr>
<td>G. Morse</td>
<td>Social and Scientific Systems Inc.</td>
<td>Renewal Research</td>
<td>$291,525</td>
<td>$291,525</td>
</tr>
<tr>
<td>G. Morse</td>
<td>Campbell Foundation</td>
<td>New Research</td>
<td>$80,000</td>
<td>$80,000</td>
</tr>
<tr>
<td>G. Morse</td>
<td>GlaxoSmithKline</td>
<td>New Training</td>
<td>$138,226</td>
<td>$138,226</td>
</tr>
<tr>
<td>P. Smith</td>
<td>Hoffmann-La Roche Inc.</td>
<td>New Clinical Trial</td>
<td>$129,986</td>
<td>$129,986</td>
</tr>
<tr>
<td>K. Tornatore</td>
<td>Novartis Pharmaceuticals Corporation</td>
<td>New Clinical Trial</td>
<td>$317,139</td>
<td>$317,139</td>
</tr>
<tr>
<td>B. Tsuji</td>
<td>Gustavus &amp; Louise Pfeiffer Research Foundation</td>
<td>New Clinical Trial</td>
<td>$48,050</td>
<td>$48,050</td>
</tr>
</tbody>
</table>

**Pharmacy Practice Totals**

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Current Period</strong></td>
<td><strong>Project Period</strong></td>
<td><strong>Current Period</strong></td>
<td><strong>Project Period</strong></td>
</tr>
<tr>
<td>Pharmacy Practice</td>
<td><strong>$1,783,712</strong></td>
<td><strong>$1,783,712</strong></td>
<td><strong>$7,824,617</strong></td>
<td><strong>$20,812,576</strong></td>
</tr>
</tbody>
</table>

**School Totals**

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmacy Practice</td>
<td><strong>$1,783,712</strong></td>
<td><strong>$1,783,712</strong></td>
<td><strong>$7,824,617</strong></td>
<td><strong>$20,812,576</strong></td>
</tr>
</tbody>
</table>
Pursue innovation, identify solutions, and present results to enhance the local, national, and international leadership of SUNY, UB, and the SoPPS.

Scholarship

**Pharmaceutical Sciences Publications: 2006–07**

**Balthasar, Joseph P.**


**Balu-Iyer, Sathy V.**


**Blanco, Javier G.**


**Boje, Kathleen M.**


Bhattacharya I, Raybon JJ, Boje KM: “Alterations in neuronal transport but not blood-brain barrier transport are observed during gamma-hydroxybutyrate (GHB) sedative/hypnotic tolerance.” *Pharm Res.* 01-Sep-06; 23(9):2067-2077.

**Brazeau, Daniel A.**


**Brazeau, Gayle A.**


**Fung, Ho Leung**

Fung HL, Tran DC, Fung H: “Effects of inhalant nitrates on VEGF expression: a feasible link to Kaposi’s sarcoma?” *J Neuroimmune Pharmacol.* 01-Sep-06; 1(3):317-322.

**Gao, Wenqing**


**Jusko, William J.**


Samtani MN, Jusko WJ: "Quantification of dexamethasone and corticosterone in rat biofluids and fetal tissue using highly sensitive analytical methods: assay validation and application to a pharmacokinetic study." Biomed Chromatogr. 01-Jun-07; 21(6):585-597.


**Krzyzanski, Wojciech**


**Mager, Donald E.**


**Morris, Marilyn E.**


Wang X, Morris ME: “Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2.” Drug Metab Dispos. 01-Feb-07; 35(2):268-274.


Qu, Jun


Straubinger RM, Qu J: “Proteomic approaches to the quantification of pharmacodynamic effect markers: General applications in drug target and biomarker identification.” Anticancer Research. 01-May-07; 27(3A):1373-1373.

Ramanathan, Murali


Schentag, Jerome J.


Straubinger, Robert M.


Straubinger RM, Qu J: “Proteomic approaches to the quantification of pharmacodynamic effect markers: General applications in drug target and biomarker identification.” Anticancer Research. 01-May-07; 27(3A):1373-1373.

Yu, Aiming M.

Pharmacy Practice Publications: 2006–07

Bednarczyk, Edward M.


Bhvannani, Sujata M.


DiCenzo, Robert


Forrest, Alan


Maponga, Charles C.


Morse, Gene D.


McCabe SM, Smith PF, Ma Q, Morse GD: “Drug interactions between proton pump inhibitors and antiretroviral drugs.” Expert Opin Drug Metab Toxicol. 01-Apr-07; 3(2):197-207.


Paladino, Joseph A.


Prescott, William A.


Schroeder, Walter S.


Slish, Judianne C.


Smith, Patrick F.

McCabe SM, Smith PF, Ma Q, Morse GD: “Drug interactions between proton pump inhibitors and antiretroviral drugs.” Expert Opin Drug Metab Toxicol. 01-Apr-07; 3(2):197-207.


Tsuji, Brian T.


Community Service

The care and discovery fostered by the SoPPS is extended to the community in a number of ways, provided by all members of the schools.

As New York State’s only publicly funded pharmacy school, community service and support is of primary importance.

All members of the SoPPS give back to the community in many ways: support of local charities and advocacy groups, food and clothing drives, and other volunteerism. Following are some of the focused activities:

The eleventh annual student halfway dance and charity gala raised over $8,400 for the Children’s Heart Fund (www.childrenshearts.org), a local charity supporting research on Protein-Losing Enteropathy, a disease which affects children born with complex defects of the heart.

PharmD students provided direct community service to over ninety agencies through community wellness clinics held at community centers, churches, and other outreach venues. Under the supervision of licensed pharmacists, these clinics allowed P2 and P3 students to interact with community members and provide recommendations on health management issues, as well as medication management. Health topics ranged from bone density assessments to counseling to cardiac rehabilitation.

Students also participated in our Poison Prevention Outreach Program where PharmD students visit area schools to educate children on the dangers of poisons and how medicines can look like candy and other harmless items. This program has reached 3,200 children in thirty-three schools throughout Western New York.

The SoPPS faculty and staff generously support the UB State Employees Federated Appeal (SEFA) Campaign. In 2006-07, the SoPPS again surpassed the goal contribution amount with 111 percent of the goal, also placing second overall at UB for school-based attainment of contribution goals!

The SoPPS comes together during the holidays to aid needy families in Buffalo Niagara. In the sixth year of support for this program, faculty and staff purchased gifts and household items for four families.

Service to valued community partners will continue in recognition of their support, as well as to assist them in their health-care management.
2006–07 Alumni Association Activities

The School of Pharmacy and Pharmaceutical Sciences Alumni Association supported and recognized many people and activities over the past academic year. Alumni Association dues allowed the association to award a total of six $500 need-based scholarships to P2 student Alyssa Murphy, P3 student Adam Field, and P4 students Michelle Foster, Kerrie Peterson, Patnowan Thung, and Andrea Hanson.

The school’s annual awards ceremony, held in April 2007, gave the association the opportunity to recognize two outstanding alumni members: Dean Trzewieczynski, Class of 1998, was the Orville C. Baxter Memorial Professional Practice Award recipient, and Susan Ksiazek, Class of 1982, was the Willis G. Gregory Memorial Award recipient. Dean and Susan both exemplify the professional practice of pharmacy and are proud advocates of the school and the association.

Our annual Reunion and All-Alumni Dinner Dance held in September welcomed back 113 alumni, guests, and SoPPS members. Special recognition was given to the 50th anniversary class of 1956, 25th anniversary class of 1981, and 10th anniversary class of 1996.

The Alumni Association held its annual outreach meeting at the Association of Health Systems Pharmacists Midyear Meeting which occurred in Anaheim, California, in December 2006. This meeting is the association’s prime national outreach activity and is always well attended (annual averages of 100+ attendees), allowing the opportunity to network and reconnect with alumni colleagues and school faculty, students, residents, and fellows.

Local alumni attend the association’s annual wine and cheese party to benefit alumni-supported student programs. The university’s premier art gallery, the Anderson Gallery, was the host site for this function in February 2007 at which gift basket auctions raised funds for student programming.

The Alumni Association values its important role in the school and its support of bringing our alumni colleagues together through various activities and programs.
The Willis G. Gregory Society recognizes donors who have made an annual gift of $1,000 or more to the School of Pharmacy and Pharmaceutical Sciences during the fiscal year. The society is named in honor of the school's admired dean, who served from 1890 until his retirement in 1936. Dr. Gregory was considered a visionary for his progressive views on pharmacy practice and is credited with transforming the pharmacy profession.

**Development**

Being able to enhance the quality and innovation of our school depends on the generosity and commitment of our alumni, friends, faculty, and staff whose support is critical to our school's continued success.

**Honor Roll of Donors**

We gratefully acknowledge the alumni, friends, faculty, staff, corporations, and foundations who made gifts to the school between July 1, 2006, and June 30, 2007. Through their generosity, the school received more than $1.9 million in gifts that allow us to continue training and nurturing the pharmacists, clinicians, pharmaceutical scientists, and community leaders of tomorrow.

### Willis G. Gregory Society

The Willis G. Gregory Society recognizes donors who have made an annual gift of $1,000 or more to the School of Pharmacy and Pharmaceutical Sciences during the fiscal year. The society is named in honor of the school's admired dean, who served from 1890 until his retirement in 1936. Dr. Gregory was considered a visionary for his progressive views on pharmacy practice and is credited with transforming the pharmacy profession.

#### $50,000–$99,999
- Campbell Foundation
- CVS Corporation
- Estate of Ms. Florence E. Kulick
- Metcare RX
- Pharmaceutical LLC

#### $10,000–$49,999
- Actelion Pharmaceutical Ltd.
- American Association of Colleges of Pharmacy
- BlueCross BlueShield of WNY
- Eli Lilly and Company
- Excellus Health Plan Inc.
- GenTech Scientific Inc.
- GPI Inc.
- Gustavus & Louise Pfeiffer Research Foundation
- Independent Health Association Inc.
- Schering-Plough Corporation

#### $5,000–$9,999
- Cancer Research and Prevention Foundation
- Charles and Philomena Bauda
- Chugai Pharmaceuticals Co. Ltd.
- CVS Pharmacy
- Genentech Inc.
- Harvard Medical Faculty Physicians
- Henry A. Panasci Jr.
- Charitable Trust
- Organon Inc.
- Walgreens

#### $1,000–$4,999
- American Society of Health-System Pharmacists Foundation
- Wayne & Lorraine Anderson
- Avantix Corporation
- Joseph L. Balwierzczak ’83
- Thomas & Maria Bardos
- Allen Barnett ’65
- Richard Battaglia ’53
- James ’90 & Jamie Baxter ’90
- Daniel & Gayle Brazeau ’89
- James Buckley ’53
- Joseph A. Chazan ’56
- Vince Christ ’53
- Margaret Crimaldi Quinn ’60
- Harold Ertman ’53
- Karl ’79 & Tina Fiebelkorn ’79
- Milner ’52 & Virginia Forster Terence ’91 & Christina Fullerton ’96
- Ho-Leung & Sun-Mi Fung
- Stephen ’81 & Carolyn Giroux
- Carol Giff ’75
- Stephen Groth ’92
- Hansaford Brothers Company
- Daniel Herrmann ’52
- Wai-Yung Florence Ho ’75
- Barbara Hole
- Gerald Hooley ’52
- Henry ’75 & Mary Hu
- Ronald Isaacs ’56
- J. Rutowski & Sons Inc.
- Michael ’76 & Susan Jay ’77
- Johnson & Johnson
- Stacy Johnson ’90
- Shang-Ying ’84 & Shue King
- Kmart Corporation
- George ’78 & Jennifer Lasezkay
- Gerhard Levy
- Brian Louchs ’86
- Walter ’81 & Elizabeth Ludwig ’84

*Graduates of the Last Decade (GOLD) Willis G. Gregory members

#### $50,000–$99,999
- American Society of Health-System Pharmacists Foundation
- Wayne & Lorraine Anderson
- Avantix Corporation
- Joseph L. Balwierzczak ’83
- Thomas & Maria Bardos
- Allen Barnett ’65
- Richard Battaglia ’53
- James ’90 & Jamie Baxter ’90
- Daniel & Gayle Brazeau ’89
- James Buckley ’53
- Joseph A. Chazan ’56
- Vince Christ ’53
- Margaret Crimaldi Quinn ’60
- Harold Ertman ’53
- Karl ’79 & Tina Fiebelkorn ’79
- Milner ’52 & Virginia Forster Terence ’91 & Christina Fullerton ’96
- Ho-Leung & Sun-Mi Fung
- Stephen ’81 & Carolyn Giroux
- Carol Giff ’75
- Stephen Groth ’92
- Hansaford Brothers Company
- Daniel Herrmann ’52
- Wai-Yung Florence Ho ’75
- Barbara Hole
- Gerald Hooley ’52
- Henry ’75 & Mary Hu
- Ronald Isaacs ’56
- J. Rutowski & Sons Inc.
- Michael ’76 & Susan Jay ’77
- Johnson & Johnson
- Stacy Johnson ’90
- Shang-Ying ’84 & Shue King
- Kmart Corporation
- George ’78 & Jennifer Lasezkay
- Gerhard Levy
- Brian Louchs ’86
- Walter ’81 & Elizabeth Ludwig ’84

*Graduates of the Last Decade (GOLD) Willis G. Gregory members

#### $100,000+
- Amgen Inc.
- CPL Associates LLC
- Merck & Co. Inc.
- National Multiple Sclerosis Society
- Novartis Pharmaceuticals Corporation
- Pfizer Global Research and Development Corporation
- Susan G. Komen Breast Cancer Foundation

#### $5,000–$9,999
- Cancer Research and Prevention Foundation
- Charles and Philomena Bauda
- Chugai Pharmaceuticals Co. Ltd.
- CVS Pharmacy
- Genentech Inc.
- Harvard Medical Faculty Physicians
- Henry A. Panasci Jr.
- Charitable Trust
- Organon Inc.
- Walgreens

#### $1,000–$4,999
- American Society of Consultant Pharmacists

*Graduates of the Last Decade (GOLD) Willis G. Gregory members

#### $100,000+
- Amgen Inc.
- CPL Associates LLC
- Merck & Co. Inc.
- National Multiple Sclerosis Society
- Novartis Pharmaceuticals Corporation
- Pfizer Global Research and Development Corporation
- Susan G. Komen Breast Cancer Foundation

### Development

Being able to enhance the quality and innovation of our school depends on the generosity and commitment of our alumni, friends, faculty, and staff whose support is critical to our school's continued success.
“Being a Willis G. Gregory member identifies the fact that you believe that the School of Pharmacy gave you the opportunity for your success.”

Bruce Moden, BS ’57

1886 Club
Honoring the generosity of our alumni and friends who recognize the historical significance of the school through their gifts of $500–$999.

2121 Main Street
Pharmacy Inc.
Charles ’67 & Carol Bainbridge ’68
Carol H. Barr ’55
Spencer ’56 & Marlene Bickel
Brooks Pharmacy
Elaine Cozzarin ’69
Cuba Pharmacy
Raymond & Mary Ann Dannenhoffer

Forster’s Pharmacy Inc.
Gail Guzzo ’70
Landfall Therapeutics Consulting Group LLC
Hung Le ’73
Ruth Lindblad ’48
Middleport Family
Health Center
Svein Oie ’75 & Barbara Woodruff

Pharmacists’ Association of Western New York
Pharmacy Society of Rochester
Debra Ley Porter ’95
Thomas Quinlan ’67
Margaret Rapp ’71
Edward and Jennifer Sawicki
Nadia Seifin ’85
Nicholas Wolfgang ’94

Profile in Giving

The Bauda Family

If you want to talk about the Bauda family tree, better make it an oak. This clan of twelve children grew up, by and large, during the Depression. But they weathered it “amazingly well,” says Dr. Charles Bauda (’42), taking motivation and strength from their mother’s belief in education. Born in Italy, his mother was about six years old when she arrived in the United States. Enrolled in a public grammar school for eight years, she “had no opportunity for higher education,” Dr. Bauda remembers. “But she inspired us to seek a college education.”

Though the family was big, they were “extremely close,” says Dr. Bauda. “We helped each other out and achieved our goals even during the years of the Depression.”

Interestingly, several Baudas entered the health-care arena. Three of them—Samuel (’23), Jennie (’26), and Joseph (’39)—graduated from the School of Pharmacy. Each saw significant success in the field. Samuel began his career with a drugstore chain. His affinity for helping customers led him to start what became a large Jamestown, New York, drugstore, which he operated for some fifty years.

Joseph had an outstanding career as a community pharmacist. He was diligent in filling prescriptions, establishing a close rapport with customers to ensure they understood how to take their medications. He also applied his administrative and organizational skills in the pharmacy field at the city, county, and state levels. A founder of the Pharmacists’ Association of Western New York, he received many awards and honors on behalf of numerous pharmacy organizations.

Jennie was a trailblazer. The first female manager of a local drugstore chain, she later ran her own store and then served as chief of pharmacy for a hospital. Recalls Dr. Bauda, “That was unheard of at that time. Jennie’s unprecedented achievement established a legacy for women pharmacists to have job opportunities equal to men.”

In addition to his pharmacist siblings, Dr. Bauda also had a brother who was an engineer, also a graduate of UB. He has honored his siblings with awards and scholarships in their names. “They made sacrifices,” he says, “to help me continue in school. In gratitude for their benevolence, I’m privileged to pay tribute to them in this way.”
MORTAR AND PESTLE CLUB

Honoring alumni and friends who contribute $250–$499 annually.

Akron Pharmacy/Town Country Gifts
Alden Pharmacy Inc.
Linda Moden Andrews ’97
Avery’s Pharmacy Inc.
Bailey Prescription Center Inc.
Robert Barr ’39
Beaver Pharmacy
Donald & Hildegard Berdine ’72
Bristol-Myers Squibb Foundation Inc.
Rebecca Bubel ’94
Paul Dalecki ’73
Michael Darby ’80

Ellicottville Pharmacy
Herbert Fechter ’56
Louisa Fiasco ’88
Roxanne Fratezi ’98
Varun Garg ’94
Bernard & Sylvia Giordano ’50
William Glave ’70
GlauxSmithKline Foundation
Sylvie Gregoire ’86
James Guerra ’39
Holland Pharmacy Inc.
Ivy Lea Drugs
Kevin Jinks ’92
James Johnson ’39
Michael Johnson ’92
Kenmore RX Center
Patricia Keys ’78
Janet Leung ’97
Suresh Marathe ’88
Edward McNiff ’83
James ’70 & Catherine Miles
Moog Inc.
Gary Mosher ’67
Raymond Napierala ’66
Gary Osborne ’79
Parkview Health Service Inc.
Petersen Drug Company
of Newfane
Pine Pharmacy & Home Care Center
Prizel’s Pharmacy
David Pysz ’76
Nancy Sager ’83
Carme ’72 & Liza Salvemini
William Schack ’61
Donald Schneider ’72
Lynée Shum ’88
Sprout’s Drug Store Inc.
John Stahl ’78
Washington Prescription Center Inc.
Lisa Webster ’84
Gerald Wemple ’93
Karen Whalen ’86

CENTURY CLUB

Honoring alumni and friends who contribute $100–$249 annually.

Jean Albert ’74
Terrence Attea ’06
Teresa Baldassaro ’91
Carrie Bartolotta ’00
Thomas Bartow ’76
Robert Begert ’72
Susan Bell ’74
Terrance Bellnier
Joseph Bertino Jr. ’76
Theresa Bianco ’84

Richard Ersing ’68
Ethan Allen
Stuart Feldman ’69
Fernando & Linda Ferreira ’84
Joseph Figlov ’70
Robert Fournette ’99
Bryan Gardner ’02
Peter ’63 & Sally Goliber
Joel Goodrich ’59
Thomas Goss ’89
Ronald Greenbaum ’79
Leo Grossman ’65
Paul Grout ’71
Lynda Haberer ’80
Robert Hammond ’65
Leroy Hanchett ’88
Steven Hansel ’93
Marcia Harris ’78
Andrea Hess ’90
Robert ’69 & Patricia Hewitt ’69
Julie Ann Hostetler ’91
Susan Hughes ’86
Eugene Hughto Jr. ’81
Anne Hulsiesten ’01
Peter Kevin Illig ’80
Cheryl Infantiino ’01
Herman Honwai Ip ’90
Ruba Jadallah ’96
James & Margaret Johnson ’79
Alykhan Kassam ’05
Kinney Drugs Inc.
Craig Kirkwood ’83
Lawrence Kocher
Karen Krutchick ’77
Paul Kunkemoeller ’80
Ronald Paul Lamb ’68
Stuart Lavallee ’83
David & Jill Lawson ’88

John ’84 & Janet Leone
John Lettieri ’78
Jeanne Adair Lill ’75
Paul Lipinoga ’73
Harvey Lisch ’83
Wendy Longden ’88
Wai Yu Loong ’91
Dave Lutomski ’79
James Mack ’75
Joan Maitino ’84
Diane Mangus ’66
Salvatore Matteliano ’79
Richard Matthys ’66
Lauren Matyjas ’02
Michael Mayersohn ’71
Paul Mazur ’86
Marian McLaughlin ’84
William ’52 & Florence McMahan ’51
Norrine McMillan ’65
Patrick Meek ’92
Karl Metzger ’82
Michael Mierzwa ’69
Stephen Morton ’00
Joseph Mroczynski ’53
Edward Mroszczak ’67
N. Chris Nwankwo ’83
Timothy O’Neill ’79
Donald Perrier ’73
Phillip Pevonia ak ’76
Stanley Piskorowski ’80
Barbara Race ’90
Nurur Rahman ’98
Dennis Resetas ’78
Diana Richardson ’82
Norman Richter ’68
Jeffrey ’68 & Margaret Rosner ’68
Joel Ross ’68
Sandra Rozek ’78
Bruce Sakowitz ’78
Abdulla Saleh ’94
Ronald ’81 & Sandra Sinatra Schifano ’80
Marlene Kieta Schmitt ’58
Jeffrey Scott ’02
Mary Priscilla Sedgwick ’81
Gerald Senses Sr. ’73
Gary Senf ’74
Zakar Peter Shakarjian ’52
Danny Dahying Shen ’75
Hsien-Chen Shih ’82
Sampat Singhvi ’74
Sharon Sipowicz ’85
David Smith ’75
Christine Sorkness ’73
Lauren Stotz ’86
Thomas Streeter ’80
Haoming Sun ’90
Pingzhong Tan ’94
Ionut Teaca ’03
Gregory Thurber ’06
David Tober ’88
James Tyson ’59
Walt ’86 & Lynn Uber ’86
Robert Vacca ’66
Mary Walker ’04
Brian White ’82
John Whitehead ’62
John Wiernikowski ’87
Daniel Winters ’76
Robert Wojtyn ’90
Kristy Wood ’06
Ralph Wynn ’69
Aiming Yu
Anne Zajicek ’85
Christopher ’79 & Dyann Zusi
The Cecil and Violet Newton Scholarship has allowed me to focus on my studies and has brought me one step closer to achieving my professional goals. I am so grateful alumni see the value in supporting future pharmacists.

Amy Hall, PharmD ’09
The Hayes Society honors individuals who have made provisions to the School of Pharmacy and Pharmaceutical Sciences through a bequest or other method of deferred giving.

Anonymous  
Thomas J. Bardos  
Allen Barnett ’65  
Thomas Blanchard ’61  
Dan & Gayle Brazeau ’89  
Robert ’53 & Nina Doran ’53  
Pamela Maude Emerson ’52

Vincent Esposito ’75  
Joseph Figlow ’70  
Edward ’52 & Jean Frank ’54  
Carol Gloff ’75  
Joel Goodrich ’59  
Jan ’59 & Rose Mary Madejski ’59

Robert ’59 & Sharon Miller  
DeWitt Niles ’62  
Robert Ravin ’57  
Irv Sultz ’55  
Howard Wright Jr. ’32

THE MATCHING GIFT PROGRAM

You may be able to double or even triple your gift to the school by taking advantage of your employer’s corporate matching gift program.

Such programs allow you to receive credit for the full amount of your gift—your contribution plus the company’s match. Eligible donors may also include retired employees and employees’ spouses, depending on your employer’s matching gift policy.

Just request and complete the matching gift form from your company’s human resources office and send it, along with your gift payable to the University at Buffalo Foundation/Pharmacy.

For more information, contact Leigh Yates, director of development, at (716) 645-3432 or ltyates@buffalo.edu.
Thank you to the many donors who have established scholarship and fellowship endowments and given annual gifts that provide much needed support to fund our highest priority—helping bright, hard-working students fulfill their dreams of obtaining their pharmacy and pharmaceutical sciences degrees. During the 2006–07 academic year, 340 students received academic and need-based scholarships and fellowships totaling $357,715.

Aversano-Strozzi Scholarship Fund
Kristen Pregizer

Jeannie Bauda DeMuth Scholarship Fund
Alison Hynes

Robert M. Cooper Memorial Award
Lynn Monteleone
Megan Todd

Crimaldi-Madejski Scholarship Fund
Kathryn Jones

CVS Scholarship Fund
Kathleen Connolly
Gifty Edusei
Brent Footer
Azaliah O’Banyoun
Krystel Otto
Wen Qiao Li
Jeffrey Scull
Matthew Waltz

X. Dave D’Ambrosio Scholarship Fund
Andrea Hanson

Lyle A. Graves Scholarship Fund
Quynh-Huong Bui
Matthew Duell
Michele Dutka
Sarah Hall
Jennifer Hedrick
Nathan Johnson
Stacey Kensey
Colleen Kingsbury
May Leong
Krista Noto
Mina Park
Danielle Patti
Rohan Raikar
Sabrina Randazzo
Marina Rozov
Jeffrey Scull
Paul Stoyell
Nathaniel Turck
Nicole Wahl
Stephen Webster
Matthew Waltz
Ethan Wong

Independent Health Scholarships
Quynh-Huong Bui
Ekaterina Kossykh-Burrows
Meghan Groth

John Kapoor Fellowship in Pharmaceutical Sciences
Kavitha Bhasi
Anu Shilpa Gandhi
Shweta Urva

Loren Larwood Scholarship Fund
Robert Adams
Nicole Barone
Elizabeth Briggs
Alexandra Centeno
Patrick Comerford
Nicole Dean
Michelle Foster
Kwaku Marfo
Richard Orlando
Jared Reles
Kristin Spencer
Amy Wong

Francis and Edward Mayer Scholarship Fund
Christopher Coleman
Karen Koller
Elizabeth Lyboult
Ronald Rambally
Jeffrey Scull

Edward Eli Neeman Scholarship Award
Matthew Duell

National Association of Chain Drug Stores Foundation Scholarships
Julia Houseknecht
Alison Hynes
Bhavesh Patel
Amanda Poworoznek

Cecil and Violet Newton Scholarship Fund
Jennifer Alberico
Robert Angelo
Jonathan Anson
Danielle Bader
James Bartlett
Gautam Bhardwaja
Amanda Blum
Amanda Bockel
Lucas Bryk
Mary Butler
James Catanes
Nicholas Clemente
Kathleen Connolly
Michael Cook
Erie Corica
Jordan Csat
Sheetal Desai
Kevin DiGiacomo
Johnathan Dittmar
Gifty Edusei
Alina Eisen
Adam Field
Evan Fleischman
Charles Greenberg
Matthew Grimm
Brian Guzwa
Binh Ha
Amy Hall
Andrea Hanso
Erica Herman
Michael Holowachuk
Lisa Imbrogno
Lisa Kenny
Kathleen Kittleson
Amy Konrad
Wen Qiao Li
William Loefller
Timothy Lyons
Jessica Massey
Robert Maynard

UB Pharmacy Alumni Association Award
Adam Field
Michelle Foster
Andrea Hanson
Alyssa Murphy
Kerrie Peterson
Patnawon Thung

UB School of Pharmacy and Pharmaceutical Sciences Golf Scholarship
Amanda Boeckel
Deborah Liana
Kwaku Marfo
Kari Mengenhagen
Kerrie Peterson
Kathy Truong

UB School of Pharmacy and Pharmaceutical Sciences Scholarship
Robert Adams
Anthony Altieri
Amy Hall
Kathryn Jones
Ekaterina Kossykh-Burrows
Azaliah O’Banyoun
Adam Saleh
Michael Seternus
Thao Tran
Elizabeth Yearwood

Walgreens Scholarship
James Bartlett
Erica Herman
Jared Reles
Jeremy Schrader
Kathy Truong

Walmart Scholarship
Jennifer Hedrick

Women’s Club of Columbia College Scholarship Fund
Alexandra Centeno
Alina Eisen
Jessica Massey
Shannon Rotolo
Elizabeth Yearwood
Thank you to all our sponsors who participated in the Fourth Annual Student Scholarship Golf Tournament. We received $30,000 in tournament sponsorships that allowed the school to award five scholarships to the following students: Brianna Belknap ’08, Tricia Lee Wilkins ’08, Amy Hall ’09, Alina Eisen ’09, and Lisa Nichols ’09.

**Gold Sponsors ($3,500)**
- Kinney Drugs
- Rite Aid Pharmacy

**Silver Sponsors ($2,500)**
- CVS Pharmacy
- McKesson Drugs
- Rochester Drug Cooperative
- J. Rutowski Pharmacies

**Bronze and Cart Sponsor ($1,250)**
- Brooks/Eckerd Pharmacies

**Bronze Sponsors ($1,000)**
- Fillmore Pharmacy
- Fisher’s Pharmacy
- Cuba Pharmacy
- Forster’s Pharmacy
- Niagara Hospice

**Hole Sponsors ($500)**
- 2121 Main Street Pharmacy
- Independent Health
- Walgreens Pharmacy

**Cart Sponsors ($250)**
- Akron Pharmacy
- Alden Pharmacy
- Bailey Pharmacy
- Beaver Pharmacy
- Ellicottville Pharmacy
- Holland Pharmacy
- Ivylea Drugs
- Niagara Apothecary
- Parkview Health Services
- PAWNY

**Gold Sponsors ($3,500)**
- Hannaford Supermarkets Inc.
- Middleport Family Health
- Washington/Kenmore
- Prescription Center

**Hole Sponsors ($500)**
- Peterson Drugs of Newfane
- Pine Pharmacy
- Prizel’s Pharmacy
- Rosenkrans Pharmacy
- Sprout’s Drug Store
- Lockport and Medina Medicine Shoppe

*Special thanks to Ethan Allen Medical Search for their contribution.*

---

**Profile in Giving**

**The Brazeaus**

Daniel and Gayle Brazeau have been a package deal for nearly thirty years now: They met in college and married soon after graduation. Received their PhDs from UB’s School of Pharmacy and Pharmaceutical Sciences. Taught at the same colleges. Wound up today—side by side, as usual—as UB pharmacy and pharmaceutical sciences school faculty.

So it should come as no surprise that they share the same philosophies on life, education, and giving. Indeed, their notion that education is “fundamental” and “transformative” led to their decision to leave a majority of their estate to UB and the pharmacy school.

The Brazeaus started wondering what they would leave as a legacy after both sets of their parents prudently prompted them to think about making a will. Their shared beliefs brought them to a logical conclusion: “We’re only going to save the planet through education,” asserts Dan, “and we’ve both been in academics our entire lives. So the idea to make the bequest to UB didn’t require a lot of thought.”

Adds Gayle, “We’re academicians at heart, so if we can invest in an environment that helps people learn every day, that’s what we’re all about. We got a great education at UB and want to make sure we can help others do the same.”

Gayle and Dan say that they love education, that giving to education is “investing in the future.” Their bequest commitment demonstrates that this long-term partnership is willing to make the investment in what they love.
The support to achieve our goals, the security to reach for the future, and the impetus for creativity are allowed through our well-positioned financial portfolio.

**A Supportive Financial Environment**

All members of the SoPPS are impacted by our positive and progressive financial planning. Financial support for the school is garnered through various avenues which include the State of New York, research activity, program and training, and philanthropic dollars. The school is fortunate to have such a varied base of support to assist in achieving our goals: the education of our students, the quest for innovative research models, the growth of scholarly activity, and the advancement of health care.

The following graphs give an overview of the school’s financial activity via revenue, expenditures, and endowments.

### Amount of Total School Revenue by Funding Source

- **State Funding**: $6,395,995
- **Grants and Contracts**: $7,798,579
- **Foundations, Auxiliaries, and Other**: $1,850,575
- **Total Revenue**: $16,045,149
School-wide Committees

Our school-wide committees give governance and oversight to our school. The structure, composition, and charges of the school's standing committees are prescribed in the bylaws of the School of Pharmacy and Pharmaceutical Sciences.

Executive Committee

Wayne Anderson (chair), Kathleen Boje, Gayle Brazeau, Rebecca Brierley, Karl Fiebelkorn, Patty Havard, William Jusko, Cindy Konovitz, Candise Morris, Gene Morse, Robert Wahler, Leigh Yates

Student Academic Affairs Committee

Karl Fiebelkorn (chair), Kathleen Boje, Gayle Brazeau, Nicole Paolini, William Prescott

Admissions Committee

Mark Sauberan (chair), Gayle Brazeau, Peter Brody, Linda Catanzaro, Karl Fiebelkorn, Fran Gengo, Cindy Konovitz, Donald Mager, William Prescott, Murali Ramanathan, Judianne Slish, Gina Zurick

Curriculum Committee

Gayle Brazeau (chair), Karl Fiebelkorn (ex officio), Cindy Konovitz (ex officio), S. V. Balu-lyer, Stewart Brower, Patricia Grace, Marilyn Morris, Nicole Paolini, William Prescott, Sara Renzi, Kristen Garwonski (P1), Lisa Nichols (P2), Daniel Burger (P3), Lynn Monteleone (P4), Nina Widler (administrative assistant)

Safety Committee

Alfred Reiman (chair), Wayne Anderson, S. V. Balu-lyer, Vicki Rink, David Soda, Kathleen Tooley

Tenure and Promotion

William Jusko (cochair), Gene Morse (cochair), H. L. Fung, Marilyn Morris, Kathleen Tornatore

National Industrial Advisory Council

Members

Wayne Anderson
Dean
UB School of Pharmacy and Pharmaceutical Sciences

Melton Affrime
Senior Vice President
Global Clinical Pharmacology
ICON Development Solutions

Allen Barnett, ’65
Chief Executive Officer
Kinex Pharmaceuticals LLC

Lisa Benincosa, ’93
Executive Director, Clinical PK/PD
Pfizer

James Daly, ’84, ’85
Senior Vice President, North American Commercial Operations
Amgen

Karl Donn, ’79
Vice President, Global Project and Portfolio Management
GlaxoSmithKline

Ronald Evans, ’69
President
MAPS for Biotec

Pramod Gupta
Vice President, Global Development
Bausch & Lomb

Christoph Hergersberg
Global Technology Leader, Biosciences
General Electric

Margaret McGlynn, ’82, ’83
President, Vaccine Division
Merck & Co.

David Panasci
President
DHP Consulting LLC

Mario Rocci Jr., ’76, ’81
Council Chair, Chief Executive Officer
Prevalere Life Sciences

Daniel Salazar, ’89
Vice President, Translational Medicine and Clinical Pharmacology
DaiichiSankyo Pharma

Michael Taylor, ’81
President and CEO
Ensemble Discovery Corporation

Avi Yacobi, ’75
President
Taro Research Institute
Senior Vice President
Taro Pharmaceutical Industries Ltd.